Condor Capital Management Invests $208,000 in Surmodics, Inc. (SRDX) Stock
Condor Capital Management acquired a new position in Surmodics, Inc. (NASDAQ:SRDX) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 6,712 shares of the company’s stock, valued at approximately $208,000. Condor Capital Management owned 0.05% of Surmodics as of its most recent filing with the SEC.
A number of other institutional investors have also recently bought and sold shares of SRDX. SG Americas Securities LLC acquired a new stake in shares of Surmodics during the 3rd quarter valued at $116,000. Macquarie Group Ltd. acquired a new stake in shares of Surmodics during the 3rd quarter valued at $123,000. BNP Paribas Arbitrage SA boosted its stake in shares of Surmodics by 66.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,270 shares of the company’s stock valued at $120,000 after buying an additional 1,700 shares during the period. Municipal Employees Retirement System of Michigan boosted its stake in shares of Surmodics by 59.1% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 4,980 shares of the company’s stock valued at $154,000 after buying an additional 1,850 shares during the period. Finally, Thrivent Financial For Lutherans acquired a new stake in shares of Surmodics during the 2nd quarter valued at $226,000. 84.84% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/23/condor-capital-management-invests-208000-in-surmodics-inc-srdx-stock.html.
Surmodics (NASDAQ:SRDX) last issued its earnings results on Wednesday, November 8th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.19. The company had revenue of $20.06 million during the quarter, compared to analyst estimates of $16.98 million. Surmodics had a net margin of 5.37% and a return on equity of 6.18%. research analysts expect that Surmodics, Inc. will post -0.33 earnings per share for the current year.
In other Surmodics news, VP Joseph J. Stich sold 1,000 shares of Surmodics stock in a transaction on Monday, September 11th. The shares were sold at an average price of $27.28, for a total transaction of $27,280.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.40% of the company’s stock.
A number of equities research analysts have issued reports on SRDX shares. ValuEngine raised shares of Surmodics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub raised shares of Surmodics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Zacks Investment Research lowered shares of Surmodics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $40.00.
Surmodics Company Profile
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Stock Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related stocks with our FREE daily email newsletter.